Debate Series - Estro-events.org
Debate Series - Estro-events.org
Debate Series - Estro-events.org
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ExhibiTion<br />
Exhibitors<br />
Macromedics B.V. 2350<br />
Kouwe Hoek 18<br />
2741 PX Waddinxveen<br />
The Netherlands<br />
Contact: Jaap Drenth<br />
Phone: +31 182 389777<br />
Fax: +31 182 389778<br />
email: info@macromedics.com<br />
www.macromedics.com<br />
MD51 1840<br />
MD51 ITALY<br />
Germany/France<br />
Contact: Ernesto G. Lanzotti<br />
Phone: +39 (0)49 767833<br />
Fax: +39 049 767845<br />
Email: info@md51.com<br />
www.md51.com<br />
MD51 is the exclusive distributor in Europe<br />
of Mobetron - Mobile linear accelerator for<br />
IOERT.<br />
MedCom GmbH 4550<br />
Rundeturmstr. 12<br />
64283 Darmstadt<br />
Germany<br />
Contact: Heike Schneider<br />
Phone: +49 6151 951470<br />
Fax: +49 6151 95147 20<br />
Email: hschneider@medcom-online.de<br />
www.medcom-online.de<br />
Page 40 PROgRammE & ExhibiTiOn guidE • ESTRO 31<br />
Merck KGaA - 3500<br />
Division Merck Serono<br />
Frankfurter Straße 250<br />
64293 Darmstadt<br />
Germany<br />
Contact: Nicole Reichel<br />
Phone: +49 (0) 6151 72-0<br />
Fax: +49 (0) 6151 72-2000<br />
Email: service@merck.de<br />
www.merckgroup.com<br />
Merck Serono, a division of Merck KGaA,<br />
Darmstadt, focuses in oncology on identifying<br />
key molecules involved in the formation<br />
of cancer, which can then be used in the<br />
development of novel targeted treatments<br />
that specifically act on cancer cells. Research<br />
activities are focused on three areas:<br />
• Compounds that act directly on tumor<br />
cells<br />
• Compounds that act indirectly on tumor<br />
cells via their interaction with their local<br />
environment<br />
• Compounds that enhance the immune<br />
system<br />
The monoclonal antibody Erbitux® (cetuximab)<br />
specifically blocks the epidermal<br />
growth factor receptor (EGFR). Erbitux<br />
has now received approval in 80 countries<br />
for the treatment of metastatic colorectal<br />
cancer (mCRC) and in 77 countries for the<br />
treatment of squamous cell carcinoma of the<br />
head and neck (SCCHN). A range of new compounds,<br />
including among others the cancer<br />
vaccine Stimuvax® (BLP25 liposome vaccine)<br />
and the integrin inhibitor cilengitide, are<br />
currently undergoing clinical development.<br />
Mevion Medical Systems 5200<br />
300 Foster Street<br />
Littleton, MA 01460<br />
USA<br />
Contact: Lionel Bouchet<br />
Phone: +1 978 540 1500<br />
Fax: +1 978 540 1501<br />
Email: info@mevion.com<br />
www.mevion.com<br />
Mevion Medical Systems, Inc. (formerly Still<br />
River Systems, Inc.) is a radiation therapy<br />
company dedicated to advancing the treatment<br />
of cancer. Mevion’s flagship product,<br />
the MEVION S250 Proton Therapy System,<br />
is designed to preserve all of the treatment<br />
benefits of traditional proton therapy systems<br />
while removing the obstacles of size,<br />
cost, and complexity. Founded in 2004, Mevion<br />
is a privately held company headquartered<br />
in the Boston metropolitan area with<br />
international offices in the United Kingdom<br />
and Japan. The United States Food and Drug<br />
Administration has not cleared the MEVION<br />
S250 Proton Therapy System for clinical use.<br />
Micropos Medical AB 4970<br />
Stena Center 1<br />
SE-412 92 Gothenburg<br />
Sweden<br />
Contact: Tomas Gustafsson<br />
Phone: +46-31-772 80 99<br />
Email: info@micropos.se<br />
www.micropos.se<br />
MIM Software Inc. 410<br />
25200 Chagrin Boulevard<br />
Suite 200<br />
Cleveland, OH 44122<br />
USA<br />
Phone: 866.421.2536<br />
Fax: 216.455.0601<br />
Email: info@mimsoftware.com<br />
www.mimsoftware.com<br />
Mirada Medical 4400<br />
Oxford Center for Innovation<br />
New Road,<br />
OX4 1HR, Oxford<br />
United Kingdom<br />
Contact: Faye Murray<br />
Phone: +44 (0) 1865 261413<br />
Fax: +44 (0) 1865 261401<br />
Email: faye.murray@mirada-medical.com<br />
www.mirada-medical.com<br />
Modus Medical Devices Inc. 2150<br />
1570 North Routledge Park<br />
London ON<br />
N6H 5L6<br />
Canada<br />
Contact: Robert Yarnell<br />
Phone: +1-519-438-2409<br />
Fax: +1-519-643-0127<br />
Email: international@modusmed.com<br />
www.modusmed.com<br />
Modus Medical develops and manufactures<br />
quality assurance tools for advanced radiation<br />
therapy. Go Beyond TG 142 with eQA<br />
2.0, a complete Linac QA solution. Penta-<br />
Guide Phantom and Software for daily CBCT<br />
ESTRO 31 • PROgRammE & ExhibiTiOn guidE Page 41<br />
ExhibiTion
Change language